Artigos (23) Publicacións nas que participase algún/ha investigador/a

2015

  1. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment

    Vox Sanguinis, Vol. 109, Núm. 4, pp. 343-352

  2. Achievement of early complete donor chimerism in CD25+-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

    Experimental Hematology, Vol. 43, Núm. 1, pp. 4-13

  3. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

    Leukemia Research, Vol. 39, Núm. 3, pp. 296-306

  4. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433

  5. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale

    Journal of Geriatric Oncology, Vol. 6, Núm. 5, pp. 353-361

  6. Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group

    Medicina Clinica, Vol. 144, Núm. 7, pp. 331.e1-331.e13

  7. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation

    Circulation: Cardiovascular Quality and Outcomes, Vol. 8, pp. S12-S20

  8. GRANULOCYTAPHERESIS IN ULCERATIVE COLITIS. EXPERIENCE IN A CENTRE

    HAEMATOLOGICA, Vol. 100, Núm. Supl. 4, pp. 227

  9. Hidden among the crowd: Differential DNA methylation-expression correlations in cancer occur at important oncogenic pathways

    Frontiers in Genetics, Vol. 6, Núm. MAY

  10. IPI AND INFECTION BY EPSTEIN BARR VIRUS AS PROGNOSTIC FACTORS IN SLPT

    HAEMATOLOGICA, Vol. 100, Núm. Supl. 4, pp. 170-171

  11. Identification and characterization of novel variations in platelet G-protein coupled receptor (GPCR) genes in patients historically diagnosed with type 1 von Willebrand disease

    PLoS ONE, Vol. 10, Núm. 12

  12. In vitro evaluation of Platelet concentrates suspended in additive solution and treated for pathogen reduction: Effects of clumping formation

    Blood Transfusion, Vol. 13, Núm. 2, pp. 281-286

  13. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

    Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918

  14. POSTRANSPLANT LYMPHOPROLIFERATIVE SYNDROME: EXPERIENCE IN A CENTRE

    HAEMATOLOGICA, Vol. 100, Núm. Supl. 4, pp. 157-158

  15. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69

  16. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

    Annals of Hematology, Vol. 94, Núm. 6, pp. 947-954

  17. Rh-null phenotype caused by a complete RHAG deletion

    Transfusion, Vol. 55, Núm. 1, pp. 197-198

  18. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

    Acta Haematologica, Vol. 134, Núm. 4, pp. 215-228

  19. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial

    Clinical Infectious Diseases, Vol. 60, Núm. 3, pp. 405-414

  20. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43